Allergen immunotherapy for allergic asthma : the future seems bright

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083819" target="_blank" >RIV/00023001:_____/23:00083819 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10465144 RIV/00064190:_____/23:10001125

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S0954611123000136?token=DDC164A3F5240DC39609D5FD138BCB2F0E726160D8DF5E7BD8A4CE2D3B73A46C77080CA7FD4A6A801AC229524E31AB3F&originRegion=eu-west-1&originCreation=20230425082054" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0954611123000136?token=DDC164A3F5240DC39609D5FD138BCB2F0E726160D8DF5E7BD8A4CE2D3B73A46C77080CA7FD4A6A801AC229524E31AB3F&originRegion=eu-west-1&originCreation=20230425082054</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rmed.2023.107125" target="_blank" >10.1016/j.rmed.2023.107125</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Allergen immunotherapy for allergic asthma : the future seems bright

Popis výsledku v původním jazyce

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.

Název v anglickém jazyce

Allergen immunotherapy for allergic asthma : the future seems bright

Popis výsledku anglicky

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Respiratory medicine

ISSN

0954-6111

e-ISSN

1532-3064

Svazek periodika

210

Číslo periodika v rámci svazku

April-May

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

"art. no. 107125"

Kód UT WoS článku

000954829100001

EID výsledku v databázi Scopus

2-s2.0-85149805928